KalVista Pharmaceuticals (NASDAQ: KALV) removes Common Stock from Nasdaq

Rhea-AI Filing Summary

KalVista Pharmaceuticals, Inc. notified removal of its Common Stock from listing and registration on the Nasdaq Stock Market LLC under Form 25. The notification states the Exchange and the Issuer have complied with the procedures of 17 CFR 240.12d2-2 for voluntary withdrawal.

The filing lists Nasdaq Stock Market LLC as the submitting exchange and includes the issuer's corporate address in Wiltshire, United Kingdom. The action is described as a withdrawal/strike from listing under the cited Exchange Act rule.

Insights

Exchange Regulatory Counsel

Voluntary delisting recorded under Rule 12d2-2; procedural compliance noted.

The filing documents a Form 25 notification that the Exchange and the Issuer have followed the steps in 17 CFR 240.12d2-2 to remove the Issuer's Common Stock from Nasdaq listing and registration. This is a procedural notice rather than a disclosure of financial terms.

Timing and any subsequent effects on trading status or registration in other venues are not stated in the excerpt; subsequent filings or Exchange notices will show the effective delisting date and procedural next steps.

Key Terms

Form 25, 17 CFR 240.12d2-2, withdrawal of listing

3 terms

Form 25 regulatory

"FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION"

A Form 25 is an official filing with the U.S. Securities and Exchange Commission used to remove a company's stock or other security from a national exchange list. Investors should care because delisting often means less visibility, lower trading volume and wider price swings—similar to a product moving from a major supermarket to a small local market, which can make buying, selling and valuing the security more difficult.

17 CFR 240.12d2-2 regulatory

"Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules"

A U.S. Securities and Exchange Commission rule that describes the conditions and procedural steps for a security to be removed from public registration or reporting under the Securities Exchange Act of 1934. For investors, it matters because it explains when a company’s shares can stop being subject to regular disclosure and exchange listing rules — similar to knowing when a publicly tracked product will be discontinued and no longer send updates, which affects transparency and liquidity.

withdrawal of listing financial

"voluntary withdrawal of the class of securities from listing and registration"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 06/11/2026 - 10:25 AM Accepted by SEC EDGAR 06/11/2026 - 10:25 AM Learn about SEC filing dates

FAQ

What does KalVista (KALV) filing Form 25 mean?

It means KalVista's Common Stock is being removed from Nasdaq listing via a Form 25 notification. The filing states the Exchange and Issuer complied with 17 CFR 240.12d2-2, documenting a voluntary withdrawal or strike from listing procedures.

Will KalVista (KALV) shares still trade after this Form 25?

The Form 25 records removal from Nasdaq listing but does not state trading status or alternative venues. The filing does not provide an effective delisting date or post-delisting trading arrangements; subsequent Exchange notices typically specify those details.

Who submitted the Form 25 for KalVista (KALV)?

Nasdaq Stock Market LLC submitted the Form 25 and certified compliance with its rules under 17 CFR 240.12d2-2. The filing is signed by an exchange officer identified as Tara Petta, AVP in the excerpt.

Does the Form 25 disclose financial terms or proceeds for KALV?

No. The excerpt documents procedural removal from listing and cites regulatory provisions; it contains no financial amounts, proceeds, or transaction consideration related to the delisting.

UNITED STATES

OMB APPROVAL

OMB Number:			3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:			1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

001-36830

Issuer:	KalVista Pharmaceuticals, Inc.
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	Building 227 Tetricus Science Park
	Porton Down
	Salisbury, Wiltshire	UNITED KINGDOM	SP4 0JQ
Telephone number:					44 (0) 1980 753002

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Common Stock

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2026-06-11	By	Tara Petta		AVP
Date		Name		Title

¹ Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.